MedRx Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	3	-	7	9	8
Other Revenue	125	257	22	50	-
Revenue	128	257	29	59	8
Revenue Growth (YoY)	-50.20%	786.21%	-50.85%	637.50%	-93.04%
Cost of Revenue	2	-	3	3	2
Gross Profit	126	257	26	56	6
Selling, General & Admin	1,068	203	221	232	270
Research & Development	-	846	737	921	794
Operating Expenses	1,068	1,050	960	1,157	1,067
Operating Income	-942	-793	-934	-1,101	-1,061
Interest Expense	-	-	-	-	-1
Interest & Investment Income	2	-	-	-	-
Currency Exchange Gain (Loss)	-5	-1	11	-3	1
Other Non Operating Income (Expenses)	8	40	-7	-8	-12
EBT Excluding Unusual Items	-937	-754	-930	-1,112	-1,073
Gain (Loss) on Sale of Investments	-	-68	-	-	-
Other Unusual Items	12	20	-	2	15
Pretax Income	-925	-802	-930	-1,110	-1,058
Income Tax Expense	12	4	2	1	1
Net Income	-937	-806	-932	-1,111	-1,059
Net Income to Common	-937	-806	-932	-1,111	-1,059
Shares Outstanding (Basic)	54	43	35	25	21
Shares Outstanding (Diluted)	54	43	35	25	21
Shares Change (YoY)	23.62%	24.99%	37.12%	18.76%	31.47%
EPS (Basic)	-17.44	-18.54	-26.80	-43.80	-49.58
EPS (Diluted)	-17.44	-18.54	-26.80	-43.80	-49.58
Free Cash Flow	-970	-803	-913	-1,074	-925
Free Cash Flow Per Share	-18.05	-18.47	-26.25	-42.34	-43.31
Gross Margin	98.44%	100.00%	89.66%	94.92%	75.00%
Operating Margin	-735.94%	-308.56%	-3220.69%	-1866.10%	-13262.50%
Profit Margin	-732.03%	-313.62%	-3213.79%	-1883.05%	-13237.50%
Free Cash Flow Margin	-757.81%	-312.45%	-3148.28%	-1820.34%	-11562.50%
EBITDA	-929	-755	-889	-1,055	-1,001
EBITDA Margin	-	-293.77%	-	-	-
D&A For EBITDA	13	38	45	46	60
EBIT	-942	-793	-934	-1,101	-1,061

Source: S&P Global Market Intelligence. Standard template. Financial Sources.